IBT
VRTX icon

International Biotechnology Trust’s Vertex Pharmaceuticals VRTX Stock Holding History

International Biotechnology Trust’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$7.3M Hold
21,000
– – 2.46% 15
2023
Q2 		$7.39M Sell
21,000
-12,000
-36% -$4.04M 2.25% 14
2023
Q1 		$10.4M Buy
+33,000
New +$9.9M 2.9% 10
2022
Q2 		– Sell
-25,122
Closed -$3.23M – 81
2022
Q1 		$3.23M Sell
25,122
-52,100
-67% -$12.4M 0.73% 33
2021
Q4 		$17M Hold
77,222
– – 3.78% 10
2021
Q3 		$14M Buy
77,222
+12,400
+19% +$2.42M 3.38% 11
2021
Q2 		$13.1M Sell
64,822
-20,500
-24% -$4.29M 3.45% 10
2021
Q1 		$18.3M Sell
85,322
-12,000
-12% -$2.64M 4.85% 8
2020
Q4 		$23M Buy
97,322
+32,500
+50% +$7.46M 6.28% 3
2020
Q3 		$17.6M Hold
64,822
– – 5.69% 6
2020
Q2 		$18.5M Sell
64,822
-13,000
-17% -$3.52M 6.14% 4
2020
Q1 		$18.5M Sell
77,822
-15,600
-17% -$3.58M 8.44% 1
2019
Q4 		$20.4M Buy
93,422
+9,400
+11% +$1.9M 7.36% 1
2019
Q3 		$14.2M Sell
84,022
-1,000
-1% -$177K 6.58% 3
2019
Q2 		$15.6M Buy
85,022
+33,900
+66% +$5.93M 5.78% 2
2019
Q1 		$9.4M Sell
51,122
-39,000
-43% -$7.2M 3.47% 6
2018
Q4 		$11.7M Buy
90,122
+22,400
+33% +$3.88M 7.28% 2
2018
Q3 		$10M Sell
67,722
-15,500
-19% -$2.76M 4.76% 4
2018
Q2 		$14.1M Buy
83,222
+15,000
+22% +$2.33M 5.43% 3
2018
Q1 		$11.1M Sell
68,222
-7,200
-10% -$1.18M 4.34% 8
2017
Q4 		$11.3M Sell
75,422
-13,300
-15% -$1.97M 3.99% 6
2017
Q3 		$13.5M Sell
88,722
-46,800
-35% -$7.04M 5.25% 4
2017
Q2 		$17.5M Buy
135,522
+13,000
+11% +$1.56M 6.64% 3
2017
Q1 		$13.4M Buy
122,522
+17,000
+16% +$1.5M 5.13% 6
2016
Q4 		$7.78M Buy
+105,522
New +$8.59M 3.5% 11

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

International Biotechnology Trust's VRTX Position: Q3 2023 in Review

International Biotechnology Trust held its Vertex Pharmaceuticals (VRTX) position steady in Q3 2023 at 21,000 shares worth $7.3M. The position accounts for 2.46% of the portfolio, ranked #15.

International Biotechnology Trust first reported a position in VRTX in Q4 2016 and has held it in 25 quarters since. The position peaked at $23M in Q4 2020. 1,278 funds tracked by Wall St. Rank hold VRTX as of Q3 2023.

  • International Biotechnology Trust held 21,000 shares of Vertex Pharmaceuticals worth $7.3M as of Q3 2023.
  • International Biotechnology Trust left its Vertex Pharmaceuticals share count unchanged in Q3 2023.
  • Vertex Pharmaceuticals made up 2.46% of International Biotechnology Trust's portfolio in Q3 2023, its #15 holding.
  • International Biotechnology Trust first reported a position in Vertex Pharmaceuticals in Q4 2016 and has held it in 25 quarters since.
  • International Biotechnology Trust's Vertex Pharmaceuticals position peaked at $23M in Q4 2020.
  • 1,278 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2023.

Based on International Biotechnology Trust's 13F filing for Q3 2023, filed 14 Nov 2023.